TL;DR
Turn quiet afternoons into listening time
- Thousands of audiobooks, podcasts and originals
- Listen on your phone, tablet or Echo — also offline
- Cancel anytime
A Danish observational study found that people with Type 2 diabetes who used statins had a lower recorded risk of dementia, but it cannot establish that the drugs caused the difference. Separately, the investigational drug obicetrapib lowered a blood Alzheimer’s biomarker in a subgroup of a Phase 3 trial; whether that translates into preventing or treating Alzheimer’s is unknown.
Two recent lines of research have reopened a question about cholesterol-lowering drugs and Alzheimer’s: a Danish records study associated statin use with lower dementia risk among people with Type 2 diabetes, while a trial of investigational drug obicetrapib found reduced levels of an Alzheimer’s-related blood biomarker in some participants. Neither result shows that lowering cholesterol prevents or treats Alzheimer’s, and the clinical meaning of the biomarker change is not yet known.
In a study published in Lancet Regional Health – Europe, researchers led by Shoaib Afzal of Copenhagen University Hospital examined electronic health records for more than 130,000 people in Denmark with Type 2 diabetes. According to Afzal’s account to Being Patient, people who started statins earlier had a 15% lower dementia risk over a decade; those who began later had a 10% lower risk. These are associations from an observational study, not proof that statins caused the difference or that the outcome was specifically Alzheimer’s disease.
The second finding came from research on obicetrapib, an investigational CETP inhibitor developed by NewAmsterdam Pharma. In a subgroup of 1,727 participants with the ApoE4 risk gene in a Phase 3 study involving people with heart disease or inherited high cholesterol, the drug lowered blood levels of pTau-217, a biomarker used in Alzheimer’s assessment. That trial was not described as showing improved memory, cognition, or Alzheimer’s symptoms.
NewAmsterdam has enrolled the first participant in a Phase 2b Alzheimer’s trial to test whether a year of obicetrapib treatment changes Alzheimer’s biomarkers in people who have disease hallmarks but no symptoms. That study is a step toward testing the hypothesis; it is not evidence that the drug is an Alzheimer’s treatment.
Why Biomarker Changes Need Testing
The findings matter because statins are widely used to reduce cardiovascular risk, and people with Type 2 diabetes are often prescribed them to lower stroke risk, including in some cases when cholesterol levels are normal. If the association with dementia reflects a real protective effect, it could have implications for a large patient population. But differences between people who take and do not take statins may explain some or all of the observed result.
Obicetrapib’s biomarker result offers a different research lead. A change in pTau-217 may justify testing whether the drug affects Alzheimer’s biology, but a blood-marker change is not the same as preventing disease or preserving cognition. The upcoming trial will help show whether that signal holds in a group selected for Alzheimer’s-related findings; further clinical research would still be needed to establish meaningful benefit.
Products Worth Considering
Sinimaka 10-Pack Twin-Wall Polycarbonate Greenhouse Panels, 8 × 4 ft
Greenworks 40V String Trimmer and Blower Combo with 2.0 Ah Battery
Husqvarna 122C 22-cc 2-Cycle Gas String Trimmer, 17-Inch Curved Shaft
As an affiliate, we earn on qualifying purchases.
What Earlier Statin Trials Found
Earlier randomized, placebo-controlled studies of statins did not find that the drugs treated cognitive decline. A separate randomized trial in healthy adults older than 70 also failed to find an effect on dementia prevention. These results have limited the case for prescribing statins specifically to prevent Alzheimer’s, even as the drugs remain used for established cardiovascular reasons.
Researchers cited by Being Patient said trial length and the timing of treatment could affect what studies detect. However, longer prevention trials may be difficult to fund: David Knopman, a Mayo Clinic neurologist, said generic, off-patent statins offer drug companies less financial incentive to sponsor costly long-term research. The biological question is also distinct from ordinary blood cholesterol: cholesterol in the blood does not pass into the brain, although abnormal cholesterol processing within the brain is under study.
“We could follow people almost up to 20 years.”
— Shoaib Afzal, chief physician and professor at Copenhagen University Hospital
What the Findings Cannot Show
The Danish study cannot rule out differences in health, medical care, or behavior between statin users and non-users. Knopman told Being Patient that statin users may be more medically informed or more likely to follow healthy behaviors, which makes the groups difficult to compare. The reported risk reductions therefore should not be read as proof of a drug effect.
For obicetrapib, the available report does not establish whether the biomarker reduction corresponds to changes in brain function, symptoms, or future dementia risk. It is also unclear whether either finding applies to people without Type 2 diabetes or to patients at different stages of Alzheimer’s. No results from the new Phase 2b trial were provided.
The Obicetrapib Trial’s Next Test
The next reported milestone is the Phase 2b study of obicetrapib in people with Alzheimer’s hallmarks but no symptoms. It is designed to examine whether a year of treatment can lower Alzheimer’s biomarkers. Researchers and readers will need results from that trial to judge whether the signal seen in the Phase 3 subgroup appears in the intended study population.
Even if biomarkers change again, later research would be needed to determine whether treatment improves or preserves cognition or delays disease. For now, the evidence does not support treating cholesterol reduction as a proven way to prevent or treat Alzheimer’s. People should make cholesterol-treatment decisions with a qualified health professional, based on their individual medical needs, rather than on these early dementia findings.
Key Questions
Has lowering cholesterol been shown to prevent Alzheimer’s?
No. The Danish study found an association between statin use and lower recorded dementia risk in people with Type 2 diabetes, but it cannot show that statins caused the difference. Earlier randomized trials did not establish dementia-prevention benefit.
Did obicetrapib improve memory or treat Alzheimer’s?
The reported Phase 3 finding was a reduction in blood pTau-217 in a subgroup carrying the ApoE4 risk gene. The source did not report improved memory, cognition, or Alzheimer’s symptoms.
What is the new obicetrapib study testing?
The Phase 2b trial is testing whether a year of treatment lowers Alzheimer’s biomarkers in people who have disease hallmarks but no symptoms. It will not, by itself, establish whether the drug prevents dementia or improves daily functioning.
Should people take statins to reduce Alzheimer’s risk?
The evidence described here does not establish statins as Alzheimer’s prevention or treatment. Statins may be prescribed for cardiovascular reasons; discuss personal treatment decisions with a qualified health professional.
Source: rss
